Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday.
That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone.
The price of the new shares would depend on the firm’s average share price over the five days before the secondary offering, Chang said. Companies usually offer discounts of up to 30 percent, she said.
As Senhwa Biosciences shares have stayed above NT$100 in the past few months, the company expects to raise at least NT$1.5 billion from the issuance of 15 million new shares, Chang said.
The fresh funds would fuel the company’s research and development of Silmitasertib, or CX-4945, which is a small-molecule drug for cancers, such as bile duct cancer, but has shown potential to combat the novel coronavirus with its capability to curb replication of the ribonucleic acid virus.
The company plans to test the drug on mice to evaluate its efficacy in cooperation with the US National Institutes of Health (NIH) next month, Senhwa Biosciences chief executive officer Soong Tai-sen (宋台生) said by telephone yesterday.
The preparation of the animal tests would take some time, as the mice first need to be genetically engineered to have a human version of a protein known as the angiotensin-converting enzyme 2 receptor, which the coronavirus uses as its point of entry, Soong said.
He expects the animal tests to be completed by the end of next month.
As conducting human tests with the experimental drug would be expensive, with an average cost of US$80,000 per subject, Senhwa Biosciences plans to apply to foreign agencies, such as the US Biomedical Advanced Research and Development Authority, for sponsorship, Soong said.
“Although the development of vaccines against COVID-19 is eye-catching, I think drugs will be the real solution for the pandemic, as COVID-19 antibodies might fade in less than two months, according to recent studies,” Soong said.
Senhwa Biosciences shares advanced 9.96 percent to NT$139.5 in Taipei trading yesterday, after an international team led by researchers at the University of California, San Francisco, identified Silmitasertib as one of the several drugs that could disrupt the viral takeover of cells.
The company’s shares have risen 120 percent from NT$63.5 in March, when the company began focusing on exploiting the experimental drug to treat COVID-19.
TECH BOOST: New TSMC wafer fabs in Arizona are to dramatically improve US advanced chip production, a report by market research firm TrendForce said With Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) pouring large funds into Arizona, the US is expected to see an improvement in its status to become the second-largest maker of advanced semiconductors in 2027, Taipei-based market researcher TrendForce Corp (集邦科技) said in a report last week. TrendForce estimates the US would account for a 21 percent share in the global advanced integrated circuit (IC) production market by 2027, sharply up from the current 9 percent, as TSMC is investing US$65 billion to build three wafer fabs in Arizona, the report said. TrendForce defined the advanced chipmaking processes as the 7-nanometer process or more
China’s Huawei Technologies Co (華為) plans to start mass-producing its most advanced artificial intelligence (AI) chip in the first quarter of next year, even as it struggles to make enough chips due to US restrictions, two people familiar with the matter said. The telecoms conglomerate has sent samples of the Ascend 910C — its newest chip, meant to rival those made by US chipmaker Nvidia Corp — to some technology firms and started taking orders, the sources told Reuters. The 910C is being made by top Chinese contract chipmaker Semiconductor Manufacturing International Corp (SMIC, 中芯) on its N+2 process, but a lack
Who would not want a social media audience that grows without new content? During the three years she paused production of her short do-it-yourself (DIY) farmer’s lifestyle videos, Chinese vlogger Li Ziqi (李子柒), 34, has seen her YouTube subscribers increase to 20.2 million from about 14 million. While YouTube is banned in China, her fan base there — although not the size of YouTube’s MrBeast, who has 330 million subscribers — is close to 100 million across the country’s social media platforms Douyin (抖音), Sina Weibo (新浪微博) and Xiaohongshu (小紅書). When Li finally released new videos last week — ending what has
OPEN SCIENCE: International collaboration on math and science will persevere even if the incoming Trump administration imposes strict controls, Nvidia’s CEO said Nvidia Corp CEO Jensen Huang (黃仁勳) said on Saturday that global cooperation in technology would continue even if the incoming US administration imposes stricter export controls on advanced computing products. US president-elect Donald Trump, in his first term in office, imposed restrictions on the sale of US technology to China citing national security — a policy continued under US President Joe Biden. The curbs forced Nvidia, the world’s leading maker of chips used for artificial intelligence (AI) applications, to change its product lineup in China. The US chipmaking giant last week reported record-high quarterly revenue on the back of strong AI chip
RSS